> top > docs > PMC:7283670 > spans > 54594-110505 > annotations

PMC:7283670 / 54594-110505 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 52244-52251 https://glytoucan.org/Structures/Glycans/G00021MO denotes heparin
T2 52244-52251 https://glytoucan.org/Structures/Glycans/G54161DR denotes heparin

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 46713-46716 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T2 46795-46798 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T3 48505-48510 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T4 49003-49013 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T5 50242-50247 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T6 51515-51520 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T7 52244-52251 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T8 52673-52681 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T9 52710-52718 Body_part denotes Thymosin http://purl.org/sig/ont/fma/fma67128
T10 52862-52870 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T11 52907-52915 Body_part denotes thymosin http://purl.org/sig/ont/fma/fma67128
T12 52922-52930 Body_part denotes Thymosin http://purl.org/sig/ont/fma/fma67128
T13 53035-53039 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T14 53073-53083 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T15 53112-53117 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T16 53372-53380 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T17 53531-53539 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T18 53632-53636 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T19 53819-53831 Body_part denotes Femoral vein http://purl.org/sig/ont/fma/fma21185
T20 54305-54321 Body_part denotes white blood cell http://purl.org/sig/ont/fma/fma62852
T21 54317-54321 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T22 54550-54559 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T23 54560-54564 Body_part denotes IL‐1 http://purl.org/sig/ont/fma/fma86583
T24 54680-54685 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T25 54919-54924 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T26 55086-55091 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T201 1358-1363 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T202 1701-1705 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T203 2131-2135 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T204 2223-2228 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T205 2312-2317 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T206 2461-2473 Body_part denotes T‐lymphocyte http://purl.org/sig/ont/fma/fma62870
T207 2503-2510 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T208 3007-3028 Body_part denotes Von willebrand factor http://purl.org/sig/ont/fma/fma81101
T209 3182-3189 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T210 3385-3389 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T211 3487-3491 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T212 3648-3652 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T213 4329-4333 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T214 4371-4378 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T215 4476-4479 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T216 5099-5104 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T217 6089-6095 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T218 6103-6109 Body_part denotes sputum http://purl.org/sig/ont/fma/fma312401
T219 6114-6137 Body_part denotes lower respiratory tract http://purl.org/sig/ont/fma/fma45662
T220 6744-6749 Body_part denotes mouth http://purl.org/sig/ont/fma/fma49184
T221 6835-6840 Body_part denotes mouth http://purl.org/sig/ont/fma/fma49184
T222 10755-10778 Body_part denotes upper respiratory tract http://purl.org/sig/ont/fma/fma45661
T223 10835-10858 Body_part denotes upper respiratory tract http://purl.org/sig/ont/fma/fma45661
T224 11002-11007 Body_part denotes Serum http://purl.org/sig/ont/fma/fma63083
T225 11015-11019 Body_part denotes IL‐1 http://purl.org/sig/ont/fma/fma86583
T226 11022-11026 Body_part denotes IL‐2 http://purl.org/sig/ont/fma/fma84051
T227 11081-11089 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T228 11247-11255 Body_part denotes hormones http://purl.org/sig/ont/fma/fma12278
T229 12485-12508 Body_part denotes lower respiratory tract http://purl.org/sig/ont/fma/fma45662
T230 12605-12610 Body_part denotes Serum http://purl.org/sig/ont/fma/fma63083
T231 12618-12622 Body_part denotes IL‐1 http://purl.org/sig/ont/fma/fma86583
T232 12625-12629 Body_part denotes IL‐2 http://purl.org/sig/ont/fma/fma84051
T233 12684-12692 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T234 13225-13229 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T235 13987-13991 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T236 14276-14281 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T237 14291-14296 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T238 14410-14415 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T239 14565-14572 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T240 14584-14591 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T241 14593-14607 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T242 14627-14632 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T243 14661-14666 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T244 14667-14675 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T245 14677-14681 Body_part denotes IL‐1 http://purl.org/sig/ont/fma/fma86583
T246 15415-15430 Body_part denotes Wharton's jelly http://purl.org/sig/ont/fma/fma323134
T247 15431-15453 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T248 15448-15453 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T249 15504-15514 Body_part denotes stem cells http://purl.org/sig/ont/fma/fma63368
T250 15509-15514 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T251 15634-15640 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T252 15823-15828 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T253 16623-16645 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T254 16640-16645 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T255 16752-16757 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T256 16841-16863 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T257 16858-16863 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T258 16986-16991 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T259 17205-17210 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T260 17744-17748 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T261 18458-18464 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T262 21660-21676 Body_part denotes white blood cell http://purl.org/sig/ont/fma/fma62852
T263 21672-21676 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T264 21684-21694 Body_part denotes hemoglobin http://purl.org/sig/ont/fma/fma62293
T265 21703-21711 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851
T266 21761-21768 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749
T267 22047-22057 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T268 22112-22122 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T269 23096-23100 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T270 23469-23473 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T271 24765-24769 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T272 26812-26819 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T273 28678-28691 Body_part denotes interleukin‐6 http://purl.org/sig/ont/fma/fma264829
T274 28678-28689 Body_part denotes interleukin http://purl.org/sig/ont/fma/fma86578
T275 28699-28709 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T276 28728-28735 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T277 28955-28960 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T278 29435-29456 Body_part denotes Mesenchymal stem cell http://purl.org/sig/ont/fma/fma0326143
T279 29452-29456 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T280 29697-29702 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T281 29706-29710 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T282 29824-29829 Body_part denotes lungs http://purl.org/sig/ont/fma/fma68877
T283 30058-30062 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T284 30125-30130 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T285 31067-31077 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T286 31140-31146 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T287 31218-31224 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T288 31232-31238 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T289 31300-31306 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T290 31344-31350 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T291 31367-31373 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T292 31414-31420 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T293 31514-31520 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T294 33342-33349 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T295 35487-35491 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T296 35807-35818 Body_part denotes dental pulp http://purl.org/sig/ont/fma/fma55631
T297 35819-35841 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T298 35836-35841 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T299 35855-35866 Body_part denotes dental pulp http://purl.org/sig/ont/fma/fma55631
T300 35867-35889 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T301 35884-35889 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T302 35948-35970 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T303 35965-35970 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T304 36013-36035 Body_part denotes mesenchymal stem cells http://purl.org/sig/ont/fma/fma0326143
T305 36030-36035 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T306 36115-36120 Body_part denotes lungs http://purl.org/sig/ont/fma/fma68877
T307 36146-36150 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T308 36180-36185 Body_part denotes Chest http://purl.org/sig/ont/fma/fma9576
T309 36224-36229 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T310 41191-41214 Body_part denotes upper respiratory tract http://purl.org/sig/ont/fma/fma45661
T311 41270-41293 Body_part denotes upper respiratory tract http://purl.org/sig/ont/fma/fma45661

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T133 1358-1363 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T134 2223-2228 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T135 2312-2317 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T136 4329-4333 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T137 5099-5104 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T138 6089-6095 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T139 6103-6109 Body_part denotes sputum http://purl.obolibrary.org/obo/UBERON_0007311
T140 6114-6137 Body_part denotes lower respiratory tract http://purl.obolibrary.org/obo/UBERON_0001558
T141 6120-6137 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T142 6744-6749 Body_part denotes mouth http://purl.obolibrary.org/obo/UBERON_0000165
T143 6835-6840 Body_part denotes mouth http://purl.obolibrary.org/obo/UBERON_0000165
T144 10755-10778 Body_part denotes upper respiratory tract http://purl.obolibrary.org/obo/UBERON_0001557
T145 10761-10778 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T146 10835-10858 Body_part denotes upper respiratory tract http://purl.obolibrary.org/obo/UBERON_0001557
T147 10841-10858 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T148 11002-11007 Body_part denotes Serum http://purl.obolibrary.org/obo/UBERON_0001977
T149 12485-12508 Body_part denotes lower respiratory tract http://purl.obolibrary.org/obo/UBERON_0001558
T150 12491-12508 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T151 12605-12610 Body_part denotes Serum http://purl.obolibrary.org/obo/UBERON_0001977
T152 14276-14281 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T153 14291-14296 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T154 14410-14415 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T155 14661-14666 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T156 15634-15640 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T157 15823-15828 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T158 16752-16757 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T159 17205-17210 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T160 18458-18464 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T161 19766-19771 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T162 19897-19902 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T163 19946-19951 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T164 20030-20035 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T165 21666-21671 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T166 22242-22246 Body_part denotes tube http://purl.obolibrary.org/obo/UBERON_0000025
T167 22260-22264 Body_part denotes tube http://purl.obolibrary.org/obo/UBERON_0000025
T168 22455-22459 Body_part denotes tube http://purl.obolibrary.org/obo/UBERON_0000025
T169 22473-22477 Body_part denotes tube http://purl.obolibrary.org/obo/UBERON_0000025
T170 23248-23253 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T171 23435-23440 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T172 23469-23473 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T173 24715-24720 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T174 24765-24769 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T175 25061-25066 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T176 28955-28960 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T177 30125-30130 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T178 31140-31146 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T179 31218-31224 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T180 31232-31238 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T181 31300-31306 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T182 31344-31350 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T183 31367-31373 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T184 31414-31420 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T185 31514-31520 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T186 35487-35491 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T187 35807-35818 Body_part denotes dental pulp http://purl.obolibrary.org/obo/UBERON_0001754
T188 35855-35866 Body_part denotes dental pulp http://purl.obolibrary.org/obo/UBERON_0001754
T189 36146-36150 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T190 36180-36185 Body_part denotes Chest http://purl.obolibrary.org/obo/UBERON_0001443
T191 36224-36229 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T192 41191-41214 Body_part denotes upper respiratory tract http://purl.obolibrary.org/obo/UBERON_0001557
T193 41197-41214 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T194 41270-41293 Body_part denotes upper respiratory tract http://purl.obolibrary.org/obo/UBERON_0001557
T195 41276-41293 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T196 41558-41563 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T197 46713-46716 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T198 46795-46798 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T199 48505-48510 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T200 48583-48588 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T201 50242-50247 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T202 51515-51520 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T203 53035-53039 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T204 53112-53117 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T205 53819-53831 Body_part denotes Femoral vein http://purl.obolibrary.org/obo/UBERON_0001361
T206 53827-53831 Body_part denotes vein http://purl.obolibrary.org/obo/UBERON_0001638
T207 54311-54316 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T208 54919-54924 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T209 55086-55091 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T335 29-37 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T336 41-45 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T337 258-266 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T338 290-298 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T339 894-902 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T340 935-943 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T341 1853-1861 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T342 1935-1943 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T343 2450-2459 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T344 2881-2886 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T345 3048-3053 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T346 3339-3347 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T347 3430-3438 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T348 3618-3626 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T349 3780-3788 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T350 3828-3836 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T351 3934-3942 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T352 3989-3997 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T353 4426-4428 Disease denotes CK http://purl.obolibrary.org/obo/MONDO_0017941
T354 4619-4627 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T355 4697-4705 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T356 4780-4789 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T357 4845-4864 Disease denotes respiratory failure http://purl.obolibrary.org/obo/MONDO_0021113
T358 5331-5339 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T359 5426-5434 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T360 6029-6037 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T361 6552-6560 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T362 6630-6638 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T363 7723-7725 Disease denotes GS http://purl.obolibrary.org/obo/MONDO_0005773
T364 7782-7790 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T365 7854-7862 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T366 8636-8638 Disease denotes GS http://purl.obolibrary.org/obo/MONDO_0005773
T367 8697-8705 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T368 9568-9576 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T369 9577-9586 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T370 9617-9625 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T371 9626-9635 Disease denotes Pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T372 10056-10064 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T373 10066-10075 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T374 10105-10113 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T375 11283-11291 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T376 11321-11329 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T377 11498-11505 Disease denotes sterile http://purl.obolibrary.org/obo/MONDO_0005047
T378 11795-11802 Disease denotes sterile http://purl.obolibrary.org/obo/MONDO_0005047
T379 12833-12841 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T380 12868-12876 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T381 13309-13317 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T382 13362-13370 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T383 13637-13646 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T384 13725-13734 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T385 13823-13831 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T386 14842-14850 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T387 14872-14876 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T388 14934-14942 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T389 15158-15165 Disease denotes sterile http://purl.obolibrary.org/obo/MONDO_0005047
T390 15196-15203 Disease denotes sterile http://purl.obolibrary.org/obo/MONDO_0005047
T391 15323-15331 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T392 15391-15399 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T393 15519-15527 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T394 16045-16053 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T395 16066-16074 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T396 16075-16098 Disease denotes cardiovascular diseases http://purl.obolibrary.org/obo/MONDO_0004995
T397 16376-16382 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T398 16657-16682 Disease denotes corona virus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T399 16683-16691 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T400 16790-16798 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T401 17706-17726 Disease denotes nosocomial infection http://purl.obolibrary.org/obo/MONDO_0043544
T402 17717-17726 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T403 17931-17939 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T404 18364-18376 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T405 18593-18601 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T406 18635-18643 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T407 19141-19149 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T408 19197-19205 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T409 21399-21408 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T410 21495-21504 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T411 21530-21541 Disease denotes neutropenia http://purl.obolibrary.org/obo/MONDO_0001475
T412 21556-21572 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T414 21925-21944 Disease denotes 2019‐nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T415 21935-21944 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T416 22010-22018 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T417 22058-22068 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T418 22123-22133 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T419 22764-22773 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T420 22834-22843 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T421 23335-23347 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T422 23474-23480 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T423 23660-23669 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T424 23687-23696 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T425 23702-23704 Disease denotes ET http://purl.obolibrary.org/obo/MONDO_0005029
T426 23706-23714 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T427 23817-23826 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T428 23832-23834 Disease denotes ET http://purl.obolibrary.org/obo/MONDO_0005029
T429 23852-23861 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T430 24012-24021 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T431 24426-24434 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T432 24770-24776 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T433 25148-25160 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T434 25544-25547 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T435 25642-25645 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T436 25739-25742 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T437 26520-26523 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T438 26563-26566 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T439 27256-27264 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T440 27719-27727 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T441 27738-27747 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T442 27816-27824 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T443 27825-27858 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T444 28318-28326 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T445 28327-28336 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T446 28386-28394 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T447 28395-28404 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T448 29497-29505 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T449 29506-29515 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T450 29540-29548 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T451 29549-29558 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T452 30324-30332 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T453 30415-30423 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T454 30739-30747 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T455 31134-31153 Disease denotes Acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T456 31147-31153 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T457 31184-31192 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T458 31203-31211 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T459 31212-31231 Disease denotes acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T460 31225-31231 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T461 31294-31313 Disease denotes Acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T462 31307-31313 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T463 31315-31323 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T464 31338-31357 Disease denotes acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T465 31351-31357 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T466 31374-31380 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T467 31382-31390 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T468 31408-31427 Disease denotes acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T469 31421-31427 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T470 31508-31527 Disease denotes acute kidney injury http://purl.obolibrary.org/obo/MONDO_0002492
T471 31521-31527 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T472 31712-31720 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T473 31844-31847 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T474 31942-31945 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T475 32039-32042 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T476 32890-32893 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T477 32973-32976 Disease denotes Ad5 http://purl.obolibrary.org/obo/MONDO_0011194
T478 33864-33889 Disease denotes corona virus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T479 33981-33989 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T480 35544-35569 Disease denotes corona virus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T481 35642-35661 Disease denotes respiratory failure http://purl.obolibrary.org/obo/MONDO_0021113
T482 35786-35795 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T483 35892-35900 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T484 36424-36433 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T485 36434-36443 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T486 36571-36579 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T487 36654-36662 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T488 36886-36894 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T489 37038-37046 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T490 37379-37387 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T491 37398-37402 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T492 37467-37471 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T493 37676-37684 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T494 37747-37754 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T495 38089-38097 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T496 38098-38108 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T497 38166-38174 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T498 38188-38196 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T499 38230-38238 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T500 38378-38386 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T501 39468-39477 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T502 40159-40168 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T503 40986-40995 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T504 41985-41993 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T505 42020-42032 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T506 42044-42052 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T507 42097-42109 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T508 42176-42185 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T509 42203-42215 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T510 42285-42294 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T511 42762-42771 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T512 42773-42781 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T513 42960-42969 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T514 43164-43173 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T515 43227-43236 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T516 43399-43408 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T517 43462-43471 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T518 43622-43631 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T519 43685-43694 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T520 43862-43871 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T521 43925-43934 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T522 44414-44422 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T523 44462-44470 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T524 44829-44839 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T525 44840-44847 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T526 44927-44934 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T527 45003-45010 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T528 45235-45242 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T529 45306-45313 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T530 45394-45401 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T531 45471-45478 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T532 45581-45588 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T533 45847-45854 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T534 46086-46093 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T535 46401-46408 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T536 46518-46525 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T537 46558-46562 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T538 46827-46862 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T539 46833-46862 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T540 46926-46961 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T541 46932-46961 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T542 47194-47202 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T543 47210-47219 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T544 49328-49347 Disease denotes 2019‐nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T545 49338-49347 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T546 49419-49438 Disease denotes 2019‐nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T547 49429-49438 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T548 49537-49546 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T549 49569-49588 Disease denotes 2019‐nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T550 49579-49588 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T551 49636-49645 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T552 49679-49688 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T553 49731-49750 Disease denotes 2019‐nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T554 49741-49750 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T555 50103-50138 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T556 50109-50138 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T557 50218-50231 Disease denotes renal failure http://purl.obolibrary.org/obo/MONDO_0001106
T558 50233-50255 Disease denotes multiple organ failure http://purl.obolibrary.org/obo/MONDO_0043726
T559 50493-50501 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T560 50514-50538 Disease denotes Coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T561 50557-50566 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T562 52366-52374 Disease denotes acidosis http://purl.obolibrary.org/obo/MONDO_0006022
T563 53040-53046 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T564 53132-53135 Disease denotes PCT http://purl.obolibrary.org/obo/MONDO_0008296|http://purl.obolibrary.org/obo/MONDO_0015104
T566 53399-53402 Disease denotes CRS http://purl.obolibrary.org/obo/MONDO_0007399|http://purl.obolibrary.org/obo/MONDO_0017361
T568 53407-53415 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T569 53526-53530 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T570 54855-54873 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T571 55053-55071 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T572 55218-55227 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T573 55377-55387 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T574 55445-55455 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T575 55686-55694 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 45724-45725 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 45761-45762 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 46233-46234 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 46270-46271 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 46713-46716 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T6 46795-46798 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T7 47238-47241 http://purl.obolibrary.org/obo/CLO_0001046 denotes 116
T8 47248-47250 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T9 47375-47376 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 47454-47456 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T11 47674-47675 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T12 47705-47706 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T13 48505-48510 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T14 48505-48510 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T15 48818-48826 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T16 49398-49400 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T17 50242-50247 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T18 50578-50580 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T19 50642-50643 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T20 51089-51090 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T21 51515-51520 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T22 52796-52798 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T23 52939-52941 http://purl.obolibrary.org/obo/CLO_0008954 denotes sc
T24 53035-53039 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T25 53035-53039 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T26 53571-53573 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T27 53827-53831 http://purl.obolibrary.org/obo/UBERON_0001638 denotes vein
T28 53827-53831 http://www.ebi.ac.uk/efo/EFO_0000816 denotes vein
T29 53961-53966 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T30 54311-54316 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T31 54317-54321 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T32 54406-54411 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T33 54419-54423 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T34 54588-54592 http://purl.obolibrary.org/obo/CLO_0053704 denotes IL‐8
T35 54658-54661 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T36 54664-54667 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T37 54664-54667 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T38 54668-54671 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T39 54674-54677 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T40 54674-54677 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T41 54678-54685 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T42 54919-54924 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T43 54919-54924 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T44 55086-55091 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T45 55086-55091 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T535 310-312 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T536 955-957 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T537 1162-1163 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T538 1358-1363 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T539 1398-1403 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T540 1699-1705 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T541 1773-1778 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T542 1823-1824 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T543 1881-1886 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T544 1954-1956 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T545 2223-2228 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T546 2312-2317 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T547 2849-2853 http://purl.obolibrary.org/obo/CLO_0053704 denotes IL‐8
T548 2949-2960 http://purl.obolibrary.org/obo/PR_000012867 denotes Plasminogen
T549 2961-2970 http://purl.obolibrary.org/obo/CLO_0001658 denotes activator
T550 3383-3389 http://purl.obolibrary.org/obo/CLO_0001020 denotes a cell
T551 3450-3452 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T552 3485-3491 http://purl.obolibrary.org/obo/CLO_0001020 denotes a cell
T553 3565-3566 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T554 3646-3652 http://purl.obolibrary.org/obo/CLO_0001020 denotes a cell
T555 3726-3727 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T556 3903-3904 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T557 4008-4010 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T558 4329-4333 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T559 4329-4333 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T560 4435-4437 http://purl.obolibrary.org/obo/PR_000010213 denotes Mb
T561 4642-4643 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T562 4723-4724 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T563 4740-4742 http://purl.obolibrary.org/obo/CLO_0053794 denotes 41
T564 4928-4936 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T565 5099-5104 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T566 5448-5450 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T567 5693-5697 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3, 4
T568 5709-5710 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T569 5853-5859 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T570 6114-6137 http://purl.obolibrary.org/obo/UBERON_0001558 denotes lower respiratory tract
T571 6744-6749 http://www.ebi.ac.uk/efo/EFO_0000825 denotes mouth
T572 6777-6783 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T573 6835-6840 http://www.ebi.ac.uk/efo/EFO_0000825 denotes mouth
T574 6979-6983 http://purl.obolibrary.org/obo/CLO_0001000 denotes 3, 5
T575 6996-6998 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T576 7042-7046 http://purl.obolibrary.org/obo/CLO_0001000 denotes 3, 5
T577 7059-7061 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T578 7568-7572 http://purl.obolibrary.org/obo/CLO_0053799 denotes 4, 5
T579 7699-7707 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T580 7874-7876 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T581 8073-8077 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3, 4
T582 8248-8252 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3, 4
T583 8612-8620 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T584 8820-8822 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T585 9013-9017 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3, 4
T586 9189-9193 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3, 4
T587 9218-9224 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T588 9647-9649 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T589 10137-10139 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T590 11022-11026 http://purl.obolibrary.org/obo/PR_000001379 denotes IL‐2
T591 11352-11354 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T592 11535-11536 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T593 11583-11584 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T594 11832-11833 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T595 11880-11881 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T596 12304-12312 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T597 12485-12508 http://purl.obolibrary.org/obo/UBERON_0001558 denotes lower respiratory tract
T598 12625-12629 http://purl.obolibrary.org/obo/PR_000001379 denotes IL‐2
T599 12887-12889 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T600 13015-13016 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T601 13381-13383 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T602 13833-13835 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T603 13842-13844 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T604 14246-14250 http://purl.obolibrary.org/obo/CLO_0001382 denotes 4, 8
T605 14276-14281 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T606 14291-14296 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T607 14291-14296 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T608 14358-14362 http://purl.obolibrary.org/obo/CLO_0001382 denotes 4, 8
T609 14410-14415 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T610 14515-14517 http://purl.obolibrary.org/obo/CLO_0009141 denotes ST
T611 14515-14517 http://purl.obolibrary.org/obo/CLO_0050980 denotes ST
T612 14609-14612 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T613 14619-14622 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T614 14625-14632 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T615 14661-14666 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T616 14661-14666 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T617 14690-14694 http://purl.obolibrary.org/obo/CLO_0053704 denotes IL‐8
T618 14954-14956 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T619 15272-15276 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T620 15431-15453 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T621 15504-15514 http://purl.obolibrary.org/obo/CL_0000034 denotes stem cells
T622 15547-15549 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T623 15817-15822 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T624 16110-16112 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T625 16623-16645 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T626 16664-16669 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T627 16746-16751 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T628 16809-16811 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T629 16841-16863 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T630 16986-16991 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T631 17199-17204 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T632 17737-17740 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T633 17742-17748 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T634 17803-17807 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T635 18066-18068 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T636 18138-18144 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T637 18655-18657 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T638 18931-18936 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T639 19217-19219 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T640 19638-19640 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T641 19669-19671 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T642 19748-19751 http://purl.obolibrary.org/obo/CLO_0001602 denotes a 6
T643 19748-19751 http://purl.obolibrary.org/obo/CLO_0001603 denotes a 6
T644 19748-19751 http://purl.obolibrary.org/obo/CLO_0050248 denotes a 6
T645 19748-19751 http://purl.obolibrary.org/obo/CLO_0052463 denotes a 6
T646 19855-19857 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T647 20078-20080 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T648 20168-20170 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T649 20268-20270 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T650 20344-20346 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T651 20447-20449 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T652 20848-20850 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T653 21666-21671 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T654 21672-21676 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T655 22047-22057 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T656 22047-22057 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T657 22112-22122 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T658 22112-22122 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T659 22242-22246 http://purl.obolibrary.org/obo/UBERON_0000025 denotes tube
T660 22260-22264 http://purl.obolibrary.org/obo/UBERON_0000025 denotes tube
T661 22455-22459 http://purl.obolibrary.org/obo/UBERON_0000025 denotes tube
T662 22473-22477 http://purl.obolibrary.org/obo/UBERON_0000025 denotes tube
T663 23094-23100 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T664 23469-23473 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T665 23469-23473 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T666 23750-23752 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T667 24765-24769 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T668 24765-24769 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T669 25458-25460 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T670 25556-25558 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T671 25634-25638 http://purl.obolibrary.org/obo/CLO_0053809 denotes 1E11
T672 25654-25656 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T673 25751-25753 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T674 25872-25876 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T675 26000-26006 http://www.ebi.ac.uk/efo/EFO_0000825 denotes mouths
T676 26153-26157 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T677 26233-26237 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T678 26368-26372 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T679 26476-26480 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T680 26720-26724 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T681 27110-27111 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T682 27180-27184 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T683 27322-27326 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T684 27468-27472 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T685 27870-27872 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T686 27887-27893 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T687 28227-28230 http://purl.obolibrary.org/obo/CLO_0001302 denotes 3–4
T688 28539-28540 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T689 28678-28691 http://purl.obolibrary.org/obo/PR_000001393 denotes interleukin‐6
T690 28955-28960 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T691 29435-29456 http://purl.obolibrary.org/obo/CL_0000134 denotes Mesenchymal stem cell
T692 29568-29570 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T693 29697-29702 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T694 29824-29829 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lungs
T695 30042-30045 http://purl.obolibrary.org/obo/PR_000001004 denotes CD4
T696 30051-30054 http://purl.obolibrary.org/obo/CLO_0053438 denotes CD8
T697 30056-30062 http://purl.obolibrary.org/obo/CL_0000084 denotes T cell
T698 30087-30091 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T699 30125-30130 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T700 30125-30130 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T701 30156-30160 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T702 30289-30290 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T703 30436-30438 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T704 31140-31146 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T705 31140-31146 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T706 31140-31146 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T707 31218-31224 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T708 31218-31224 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T709 31218-31224 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T710 31232-31238 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T711 31232-31238 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T712 31232-31238 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T713 31259-31261 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T714 31300-31306 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T715 31300-31306 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T716 31300-31306 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T717 31344-31350 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T718 31344-31350 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T719 31344-31350 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T720 31367-31373 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T766 36146-36150 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T721 31367-31373 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T722 31367-31373 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T723 31414-31420 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T724 31414-31420 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T725 31414-31420 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T726 31514-31520 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T727 31514-31520 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T728 31514-31520 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T729 31732-31734 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T730 31856-31858 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T731 31934-31938 http://purl.obolibrary.org/obo/CLO_0053809 denotes 1E11
T732 31954-31956 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T733 32051-32053 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T734 32190-32196 http://www.ebi.ac.uk/efo/EFO_0000825 denotes mouths
T735 32399-32403 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T736 32524-32528 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T737 32620-32624 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T738 32728-32732 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T739 32808-32812 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T740 32921-32925 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T741 33004-33008 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T742 33209-33213 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T743 33288-33292 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T744 33380-33384 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T745 33473-33477 http://purl.obolibrary.org/obo/CLO_0001313 denotes 3, 6
T746 33871-33876 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T747 34001-34003 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T748 34132-34133 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T749 34192-34193 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T750 34309-34312 http://purl.obolibrary.org/obo/CLO_0001382 denotes 4–8
T751 34657-34663 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T752 34736-34737 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T753 34796-34797 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T754 34881-34887 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T755 34936-34939 http://purl.obolibrary.org/obo/CLO_0001382 denotes 4–8
T756 35402-35406 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T757 35487-35491 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T758 35487-35491 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T759 35551-35556 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T760 35819-35841 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T761 35867-35889 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T762 35911-35913 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T763 35948-35970 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T764 36013-36035 http://purl.obolibrary.org/obo/CL_0000134 denotes mesenchymal stem cells
T765 36115-36120 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lungs
T767 36146-36150 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T768 36180-36185 http://www.ebi.ac.uk/efo/EFO_0000965 denotes Chest
T769 36224-36229 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T770 36224-36229 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T771 36590-36592 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T772 36841-36847 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T773 36935-36936 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T774 36957-36958 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T775 37435-37437 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T776 37868-37869 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T777 38796-38798 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T778 39072-39074 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T779 39311-39312 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T780 39342-39343 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T781 39976-39977 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T782 40007-40008 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T783 40239-40245 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T784 40663-40664 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T785 41556-41557 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T786 41924-41930 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T787 42062-42064 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T788 42880-42885 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T789 42899-42900 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T790 42990-42992 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T791 43028-43029 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T792 43320-43325 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T793 43339-43340 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T794 43492-43498 http://purl.obolibrary.org/obo/CLO_0001658 denotes Active
T795 43517-43518 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T796 43784-43789 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T797 43803-43804 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T798 44767-44768 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T799 45184-45185 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T800 45221-45222 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T34382 236-244 Chemical denotes adjuvant http://purl.obolibrary.org/obo/CHEBI_60809
T9718 341-346 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T25818 437-442 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T79148 462-464 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T1524 575-581 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T65175 848-851 Chemical denotes TCM http://purl.obolibrary.org/obo/CHEBI_145500
T42271 910-913 Chemical denotes TCM http://purl.obolibrary.org/obo/CHEBI_145500
T66 982-987 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T5227 1000-1003 Chemical denotes TCM http://purl.obolibrary.org/obo/CHEBI_145500
T89603 1016-1024 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T64472 1081-1096 Chemical denotes antiviral drugs http://purl.obolibrary.org/obo/CHEBI_36044
T16097 1081-1090 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T79085 1091-1096 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T84596 1113-1116 Chemical denotes TCM http://purl.obolibrary.org/obo/CHEBI_145500
T22462 1177-1182 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T20379 1192-1200 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T7585 1258-1273 Chemical denotes antiviral drugs http://purl.obolibrary.org/obo/CHEBI_36044
T86024 1258-1267 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T48066 1268-1273 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T54548 1404-1411 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T38531 1779-1790 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T17203 1887-1898 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T28054 1985-1990 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T1929 2009-2011 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T63564 2056-2061 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T84 2503-2510 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T17269 2529-2543 Chemical denotes angiotensin II http://purl.obolibrary.org/obo/CHEBI_2719|http://purl.obolibrary.org/obo/CHEBI_48432|http://purl.obolibrary.org/obo/CHEBI_58506
T19318 2529-2540 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T89 2541-2543 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T24232 2549-2551 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T91 2572-2583 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T80419 2617-2628 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T30660 2687-2698 Chemical denotes aldosterone http://purl.obolibrary.org/obo/CHEBI_27584|http://purl.obolibrary.org/obo/CHEBI_30834
T95 2718-2729 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T40933 2767-2778 Chemical denotes angiotensin http://purl.obolibrary.org/obo/CHEBI_48433
T73661 2825-2827 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T54173 2849-2851 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T70837 2917-2919 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T26545 2971-2980 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T22043 3112-3143 Chemical denotes advanced glycation end products http://purl.obolibrary.org/obo/CHEBI_84123
T80881 3171-3181 Chemical denotes surfactant http://purl.obolibrary.org/obo/CHEBI_35195
T41839 3182-3189 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T657 3961-3968 Chemical denotes citrate http://purl.obolibrary.org/obo/CHEBI_133748|http://purl.obolibrary.org/obo/CHEBI_16947|http://purl.obolibrary.org/obo/CHEBI_50744
T36666 4052-4057 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T59812 4059-4077 Chemical denotes sildenafil citrate http://purl.obolibrary.org/obo/CHEBI_58987
T48299 4059-4069 Chemical denotes sildenafil http://purl.obolibrary.org/obo/CHEBI_9139
T80763 4070-4077 Chemical denotes citrate http://purl.obolibrary.org/obo/CHEBI_133748|http://purl.obolibrary.org/obo/CHEBI_16947|http://purl.obolibrary.org/obo/CHEBI_50744
T56768 4371-4378 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T36106 5153-5165 Chemical denotes nitric oxide http://purl.obolibrary.org/obo/CHEBI_16480
T79701 5160-5165 Chemical denotes oxide http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356
T36153 5192-5198 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T54594 5356-5365 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T97769 5493-5502 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T20676 5530-5539 Chemical denotes darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T92853 5547-5557 Chemical denotes cobicistat http://purl.obolibrary.org/obo/CHEBI_72291
T46415 5618-5636 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T20639 5735-5753 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T47677 6357-6361 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T34447 6467-6486 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T27940 6467-6476 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T20411 6477-6486 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T71837 6490-6508 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T131 6569-6588 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T12779 6569-6578 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T42223 6579-6588 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T53502 6596-6614 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T77554 6615-6622 Chemical denotes sulfate http://purl.obolibrary.org/obo/CHEBI_16189
T82580 6697-6716 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T91739 6697-6706 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T7801 6707-6716 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T31954 6796-6814 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T56995 6897-6916 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T74129 6897-6906 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T14779 6907-6916 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T75588 6921-6939 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T41134 6941-6943 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T71387 7164-7170 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T58068 7416-7435 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T12331 7416-7425 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T50748 7426-7435 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T149 7439-7457 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T150 7518-7537 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T151 7518-7527 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T152 7528-7537 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T153 7542-7560 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T154 7606-7614 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T155 7689-7698 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T156 7711-7721 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T157 7723-7725 Chemical denotes GS http://purl.obolibrary.org/obo/CHEBI_73516
T158 7799-7809 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T159 8099-8109 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T160 8350-8356 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T161 8477-8481 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T162 8602-8611 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T163 8624-8634 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T164 8636-8638 Chemical denotes GS http://purl.obolibrary.org/obo/CHEBI_73516
T165 8753-8763 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T166 8865-8875 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T167 9040-9050 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T168 9461-9465 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T169 9692-9697 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T170 9725-9729 Chemical denotes NaCl http://purl.obolibrary.org/obo/CHEBI_26710
T171 9780-9785 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T172 9989-10000 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T173 10008-10016 Chemical denotes adjuvant http://purl.obolibrary.org/obo/CHEBI_60809
T174 10083-10094 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T175 10114-10125 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T176 10196-10201 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T177 10253-10264 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T178 10265-10270 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T179 10325-10327 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T180 10683-10689 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T181 11015-11017 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T183 11022-11024 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T185 11028-11030 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T187 11034-11036 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T189 11040-11042 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T191 11212-11223 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T192 11247-11255 Chemical denotes hormones http://purl.obolibrary.org/obo/CHEBI_24621
T193 11302-11306 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T194 11308-11319 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T195 11330-11341 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T196 11411-11416 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T197 11419-11429 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T198 11506-11511 Chemical denotes water http://purl.obolibrary.org/obo/CHEBI_15377
T199 11602-11620 Chemical denotes methylprednisolone http://purl.obolibrary.org/obo/CHEBI_6888
T200 11696-11707 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T201 11708-11713 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T202 11716-11726 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T203 11803-11808 Chemical denotes water http://purl.obolibrary.org/obo/CHEBI_15377
T204 11899-11917 Chemical denotes methylprednisolone http://purl.obolibrary.org/obo/CHEBI_6888
T205 11944-11955 Chemical denotes thalidomide http://purl.obolibrary.org/obo/CHEBI_9513
T206 11982-11984 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T207 12592-12596 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T208 12618-12620 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T210 12625-12627 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T212 12631-12633 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T214 12637-12639 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T216 12643-12645 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T218 12788-12799 Chemical denotes Tetrandrine http://purl.obolibrary.org/obo/CHEBI_49
T219 12989-13000 Chemical denotes Tetrandrine http://purl.obolibrary.org/obo/CHEBI_49
T220 13007-13009 Chemical denotes QD http://purl.obolibrary.org/obo/CHEBI_50853
T221 13166-13168 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T222 13423-13428 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T223 13450-13460 Chemical denotes fingolimod http://purl.obolibrary.org/obo/CHEBI_63115
T224 13471-13476 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T225 13497-13507 Chemical denotes fingolimod http://purl.obolibrary.org/obo/CHEBI_63115
T226 13579-13584 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T227 13586-13588 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T228 13892-13897 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T229 14068-14073 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T230 14297-14303 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T231 14474-14479 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T232 14515-14517 Chemical denotes ST http://purl.obolibrary.org/obo/CHEBI_141393
T233 14565-14572 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T234 14584-14591 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T235 14677-14679 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T237 14684-14686 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T239 14690-14692 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T241 14695-14697 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T243 14822-14830 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T244 14909-14917 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T245 14919-14923 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T246 15018-15026 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T247 15047-15055 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T248 15286-15288 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T249 15792-15800 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T250 16153-16158 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T251 16250-16255 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T252 16657-16663 Chemical denotes corona http://purl.obolibrary.org/obo/CHEBI_37409
T253 16767-16775 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T254 17220-17228 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T255 17299-17301 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T256 17412-17417 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T257 17630-17636 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T258 17959-17963 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T259 17965-17984 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T260 17965-17974 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T261 17975-17984 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T262 17996-18003 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T263 18007-18018 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T264 18019-18028 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T268 18157-18176 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T269 18157-18166 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T270 18167-18176 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T271 18180-18187 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T272 18191-18202 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T273 18203-18212 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T277 18238-18257 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T278 18238-18247 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T279 18248-18257 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T280 18269-18276 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T281 18280-18291 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T282 18292-18301 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T286 18303-18305 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T287 18574-18589 Chemical denotes corticosteroids http://purl.obolibrary.org/obo/CHEBI_50858
T288 18609-18627 Chemical denotes methylprednisolone http://purl.obolibrary.org/obo/CHEBI_6888
T289 18705-18710 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T290 18712-18730 Chemical denotes methylprednisolone http://purl.obolibrary.org/obo/CHEBI_6888
T291 18781-18786 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T292 19168-19172 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T293 19303-19305 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T294 19421-19423 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T295 19524-19526 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T296 19579-19581 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T297 20207-20209 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T299 20362-20364 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T301 20686-20692 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T302 20816-20822 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T303 21684-21694 Chemical denotes hemoglobin http://purl.obolibrary.org/obo/CHEBI_35143
T304 21719-21729 Chemical denotes creatinine http://purl.obolibrary.org/obo/CHEBI_16737
T305 21744-21753 Chemical denotes bilirubin http://purl.obolibrary.org/obo/CHEBI_16990
T306 21761-21768 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449
T307 21793-21802 Chemical denotes aspartate http://purl.obolibrary.org/obo/CHEBI_132943|http://purl.obolibrary.org/obo/CHEBI_29995|http://purl.obolibrary.org/obo/CHEBI_72314
T310 22174-22179 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T311 22334-22339 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T312 23702-23704 Chemical denotes ET http://purl.obolibrary.org/obo/CHEBI_73510
T313 23832-23834 Chemical denotes ET http://purl.obolibrary.org/obo/CHEBI_73510
T314 24373-24375 Chemical denotes LV http://purl.obolibrary.org/obo/CHEBI_73579
T315 24397-24404 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T316 24567-24569 Chemical denotes LV http://purl.obolibrary.org/obo/CHEBI_73579
T317 24660-24662 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T318 25500-25505 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T319 25598-25603 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T320 25694-25699 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T321 26812-26819 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T322 27138-27150 Chemical denotes nucleic acid http://purl.obolibrary.org/obo/CHEBI_33696
T323 27146-27150 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T324 27769-27787 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T325 27789-27793 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T326 28357-28368 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T327 28597-28599 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T328 28728-28735 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T329 28797-28803 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T330 28832-28838 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T331 30001-30013 Chemical denotes nucleic acid http://purl.obolibrary.org/obo/CHEBI_33696
T332 30009-30013 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T333 30131-30137 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T334 30217-30222 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T335 30295-30304 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T336 30305-30320 Chemical denotes immunomodulator http://purl.obolibrary.org/obo/CHEBI_50846
T337 30358-30362 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T338 30574-30576 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T339 30660-30668 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T340 30677-30679 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T341 30977-30985 Chemical denotes pressors http://purl.obolibrary.org/obo/CHEBI_137431
T342 31017-31023 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T343 31800-31805 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T344 31898-31903 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T345 31994-31999 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T346 33342-33349 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T347 33832-33843 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T348 33864-33870 Chemical denotes corona http://purl.obolibrary.org/obo/CHEBI_37409
T349 33897-33908 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T350 33923-33934 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T351 33936-33940 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T352 33942-33953 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T353 33955-33959 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T354 33961-33972 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T355 34033-34044 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T356 34059-34070 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T357 34071-34076 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T358 34389-34400 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T359 34676-34687 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T360 34688-34693 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T361 34900-34911 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T362 34912-34917 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T363 35016-35027 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T364 35372-35380 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T365 35389-35401 Chemical denotes nucleic acid http://purl.obolibrary.org/obo/CHEBI_33696
T366 35397-35401 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T367 35544-35550 Chemical denotes corona http://purl.obolibrary.org/obo/CHEBI_37409
T368 36230-36236 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T369 36472-36491 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T370 36472-36481 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T371 36482-36491 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T372 36534-36538 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T373 36540-36559 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T374 36540-36549 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T375 36550-36559 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T376 36636-36641 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T377 36756-36765 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T378 36776-36785 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T379 36795-36800 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T380 36801-36811 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T381 36868-36873 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T382 36896-36905 Chemical denotes Lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T383 36906-36915 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T384 36965-36970 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T385 36971-36981 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T386 37022-37027 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T387 37140-37149 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T388 37160-37169 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T389 37179-37184 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T390 37185-37195 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T391 37629-37640 Chemical denotes Chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T392 37719-37730 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T393 37732-37736 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T394 37855-37866 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T395 37892-37896 Chemical denotes base http://purl.obolibrary.org/obo/CHEBI_22695
T396 37933-37944 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T397 37945-37959 Chemical denotes phosphate salt http://purl.obolibrary.org/obo/CHEBI_37853
T398 37945-37954 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T402 37955-37959 Chemical denotes salt http://purl.obolibrary.org/obo/CHEBI_24866|http://purl.obolibrary.org/obo/CHEBI_26710
T404 38388-38391 Chemical denotes ARI http://purl.obolibrary.org/obo/CHEBI_35640
T405 38633-38637 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T406 38689-38697 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T407 38733-38741 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T408 38776-38784 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T409 38867-38872 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T410 38903-38911 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T411 39090-39098 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T412 39385-39393 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T413 39601-39606 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T414 39637-39645 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T415 40050-40058 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T416 40086-40094 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T417 40289-40297 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T418 40298-40303 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T419 40334-40342 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T420 40389-40397 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T421 40470-40478 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T422 40601-40609 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T423 40696-40704 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T424 40760-40768 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T425 40877-40885 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T426 40913-40921 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T427 41067-41069 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T428 41705-41711 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T429 42623-42647 Chemical denotes bromhexine hydrochloride http://purl.obolibrary.org/obo/CHEBI_31303
T430 42623-42633 Chemical denotes bromhexine http://purl.obolibrary.org/obo/CHEBI_77032
T431 42634-42647 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T432 42790-42814 Chemical denotes bromhexine hydrochloride http://purl.obolibrary.org/obo/CHEBI_31303
T433 42790-42800 Chemical denotes bromhexine http://purl.obolibrary.org/obo/CHEBI_77032
T434 42801-42814 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T435 42824-42828 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T436 42830-42837 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T437 42838-42851 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T438 42862-42866 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T439 42886-42896 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T440 42908-42912 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T441 42914-42925 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T442 43022-43027 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T443 43040-43045 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T444 43047-43071 Chemical denotes Bromhexine hydrochloride http://purl.obolibrary.org/obo/CHEBI_31303
T445 43058-43071 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T446 43081-43088 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T447 43089-43102 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T448 43246-43259 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T449 43326-43336 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T450 43511-43516 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T451 43527-43532 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T452 43540-43547 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T453 43548-43561 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T454 43696-43703 Chemical denotes arbidol http://purl.obolibrary.org/obo/CHEBI_134730
T455 43704-43717 Chemical denotes hydrochloride http://purl.obolibrary.org/obo/CHEBI_36807
T456 43790-43800 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T457 44343-44349 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T458 44423-44435 Chemical denotes nucleic acid http://purl.obolibrary.org/obo/CHEBI_33696
T459 44431-44435 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T460 44471-44483 Chemical denotes nucleic acid http://purl.obolibrary.org/obo/CHEBI_33696
T461 44479-44483 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T462 44679-44698 Chemical denotes protease inhibitors http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258
T464 44688-44698 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T465 44700-44711 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T466 44713-44724 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T467 44891-44902 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T468 44935-44946 Chemical denotes Oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T469 45025-45048 Chemical denotes lopinavir and ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T470 45025-45034 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T471 45039-45048 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T472 45054-45065 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T473 45066-45075 Chemical denotes Lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T474 45089-45098 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T475 45114-45125 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T476 45257-45280 Chemical denotes lopinavir and ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T477 45257-45266 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T478 45271-45280 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T479 45286-45297 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T31308 45339-45348 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T26014 45364-45375 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T28790 45416-45439 Chemical denotes lopinavir and ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T43391 45416-45425 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T42713 45430-45439 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T89000 45440-45451 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T36554 45504-45513 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T16660 45529-45540 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T77346 45603-45614 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T18123 45615-45634 Chemical denotes lopinavir/ritonavir http://purl.obolibrary.org/obo/CHEBI_145924
T7264 45615-45624 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T88178 45625-45634 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T33676 45654-45665 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T63088 45797-45806 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T27488 45869-45878 Chemical denotes darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T45665 45879-45888 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T78808 45889-45900 Chemical denotes oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T99588 45901-45912 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T5598 45939-45948 Chemical denotes Darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T87739 45967-45976 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T81794 46002-46013 Chemical denotes Oseltamivir http://purl.obolibrary.org/obo/CHEBI_7798
T65434 46029-46040 Chemical denotes Chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T38243 46108-46117 Chemical denotes darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T52708 46118-46127 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T13256 46128-46139 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T90329 46140-46151 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T83414 46281-46290 Chemical denotes darunavir http://purl.obolibrary.org/obo/CHEBI_367163
T8543 46309-46318 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T86432 46319-46328 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T81415 46344-46355 Chemical denotes chloroquine http://purl.obolibrary.org/obo/CHEBI_3638
T48024 47110-47114 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T82843 47228-47236 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T97531 47315-47320 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T34 47472-47480 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T46725 47981-47986 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T44374 48399-48401 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T54831 48511-48517 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T35025 48703-48709 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T46910 48870-48876 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T51952 49209-49213 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T53408 49439-49444 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T76646 49589-49594 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T95398 49603-49608 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T7063 49751-49756 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T59274 49787-49792 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T67786 50436-50442 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T51571 50628-50633 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T6125 50675-50689 Chemical denotes antiviral drug http://purl.obolibrary.org/obo/CHEBI_36044
T40279 50675-50684 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T78450 50685-50689 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T70786 50708-50714 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T85333 50800-50805 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T23407 51025-51030 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T89303 51065-51070 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T51321 51122-51136 Chemical denotes antiviral drug http://purl.obolibrary.org/obo/CHEBI_36044
T61015 51122-51131 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T62050 51132-51136 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T94802 51155-51161 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T11085 51279-51285 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T42076 51378-51384 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T29380 52244-52251 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T94147 52253-52267 Chemical denotes anticoagulants http://purl.obolibrary.org/obo/CHEBI_50249
T44009 52446-52452 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T5062 52486-52492 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T18722 52525-52531 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T30228 52659-52661 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T82071 52704-52708 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T76124 52780-52782 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T5320 52841-52843 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T71040 52846-52851 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T42282 52857-52859 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T9670 52880-52882 Chemical denotes IV http://purl.obolibrary.org/obo/CHEBI_74327
T65756 52916-52921 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T67187 52990-52995 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T22212 53013-53015 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T36692 53140-53142 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T72462 53423-53434 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T7025 53684-53692 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T65846 53961-53966 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T33991 54135-54141 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T19624 54399-54405 Chemical denotes corona http://purl.obolibrary.org/obo/CHEBI_37409
T15741 54560-54562 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T28024 54567-54569 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T87 54582-54584 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T26286 54588-54590 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T35 2887-2895 http://purl.obolibrary.org/obo/GO_0070265 denotes necrosis
T36 2887-2895 http://purl.obolibrary.org/obo/GO_0019835 denotes necrosis
T37 2887-2895 http://purl.obolibrary.org/obo/GO_0008219 denotes necrosis
T38 2887-2895 http://purl.obolibrary.org/obo/GO_0001906 denotes necrosis
T39 2949-2970 http://purl.obolibrary.org/obo/GO_0031639 denotes Plasminogen activator
T40 3054-3062 http://purl.obolibrary.org/obo/GO_0070265 denotes necrosis
T41 3054-3062 http://purl.obolibrary.org/obo/GO_0019835 denotes necrosis
T42 3054-3062 http://purl.obolibrary.org/obo/GO_0008219 denotes necrosis
T43 3054-3062 http://purl.obolibrary.org/obo/GO_0001906 denotes necrosis
T44 6138-6148 http://purl.obolibrary.org/obo/GO_0046903 denotes secretions
T45 18364-18376 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T46 21556-21572 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity
T47 23335-23347 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T48 25148-25160 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T601 0-51 Sentence denotes Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2
T602 52-194 Sentence denotes Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
T603 195-273 Sentence denotes The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug:
T604 274-428 Sentence denotes Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
T605 429-515 Sentence denotes Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
T606 516-815 Sentence denotes Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
T607 816-1168 Sentence denotes Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
T608 1169-1309 Sentence denotes Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days):
T609 1310-1377 Sentence denotes The relief/disappearance rate of main symptoms, chest CT absorption
T610 1378-1490 Sentence denotes Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time.
T611 1491-1614 Sentence denotes The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
T612 1615-1760 Sentence denotes Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
T613 1761-1868 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug:
T614 1869-1991 Sentence denotes Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group:
T615 1992-2047 Sentence denotes 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
T616 2048-2169 Sentence denotes Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
T617 2170-3334 Sentence denotes Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
T618 3335-3626 Sentence denotes The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
T619 3627-3902 Sentence denotes Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
T620 3903-3949 Sentence denotes A Pilot Study of Sildenafil in COVID‐19 Drug:
T621 3950-4242 Sentence denotes Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
T622 4243-4589 Sentence denotes Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
T623 4590-4789 Sentence denotes Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
T624 4790-4972 Sentence denotes 30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate:
T625 4973-4999 Sentence denotes 15% − Primary (28 days):
T626 5000-5016 Sentence denotes 28 day mortality
T627 5017-5252 Sentence denotes Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
T628 5253-5698 Sentence denotes Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4.
T629 5699-5813 Sentence denotes Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4.
T630 5814-5852 Sentence denotes Other: standard public health measures
T631 5853-6043 Sentence denotes Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
T632 6044-6452 Sentence denotes Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
T633 6453-6776 Sentence denotes Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
T634 6777-6867 Sentence denotes Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
T635 6868-6999 Sentence denotes No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
T636 7000-7655 Sentence denotes Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
T637 7656-8084 Sentence denotes Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
T638 8085-8382 Sentence denotes Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
T639 8383-8568 Sentence denotes Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
T640 8569-9025 Sentence denotes Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
T641 9026-9217 Sentence denotes Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
T642 9218-9519 Sentence denotes Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
T643 9520-9698 Sentence denotes Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
T644 9699-9754 Sentence denotes bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
T645 9755-9961 Sentence denotes No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
T646 9962-10238 Sentence denotes The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
T647 10239-10299 Sentence denotes Experimental: thalidomide group 100 mg, po, qn, for 14 days.
T648 10300-10421 Sentence denotes Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
T649 10422-10545 Sentence denotes Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
T650 10546-11184 Sentence denotes Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
T651 11185-11621 Sentence denotes The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone:
T652 11622-11655 Sentence denotes 40 mg, q12h, for 5 days. placebo:
T653 11656-11681 Sentence denotes 100 mg/d, qn, for 14 days
T654 11682-11918 Sentence denotes Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone:
T655 11919-11956 Sentence denotes 40 mg, q12h, for 5 days. thalidomide:
T656 11957-12039 Sentence denotes 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
T657 12040-12787 Sentence denotes Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
T658 12788-13069 Sentence denotes Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
T659 13070-13294 Sentence denotes No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
T660 13295-13553 Sentence denotes Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
T661 13554-13712 Sentence denotes No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
T662 13713-14039 Sentence denotes Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
T663 14040-14314 Sentence denotes Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
T664 14315-14794 Sentence denotes Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
T665 14795-15070 Sentence denotes The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2:
T666 15071-15137 Sentence denotes 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
T667 15138-15308 Sentence denotes Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days):
T668 15309-15377 Sentence denotes Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
T669 15378-15734 Sentence denotes Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
T670 15735-15903 Sentence denotes WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks):
T671 15904-15945 Sentence denotes Clinical outcome, CT Scan, RT‐PCR results
T672 15946-16023 Sentence denotes Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
T673 16024-16244 Sentence denotes Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
T674 16245-16433 Sentence denotes Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
T675 16434-16607 Sentence denotes Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
T676 16608-17039 Sentence denotes Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
T677 17040-17417 Sentence denotes Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
T678 17418-17870 Sentence denotes Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
T679 17871-18137 Sentence denotes The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
T680 18138-18550 Sentence denotes Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
T681 18551-18759 Sentence denotes Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
T682 18760-18868 Sentence denotes No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
T683 18869-19059 Sentence denotes Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
T684 19060-19338 Sentence denotes Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names:
T685 19339-19366 Sentence denotes Kevzara®, REGN88, SAR153191
T686 19367-19455 Sentence denotes Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names:
T687 19456-19483 Sentence denotes Kevzara®, REGN88, SAR153191
T688 19484-19780 Sentence denotes Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
T689 19781-21872 Sentence denotes Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
T690 21873-22305 Sentence denotes Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
T691 22306-22666 Sentence denotes Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
T692 22667-23109 Sentence denotes Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
T693 23110-23576 Sentence denotes Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
T694 23577-23909 Sentence denotes Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
T695 23910-24122 Sentence denotes Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
T696 24123-24133 Sentence denotes Secondary:
T697 24134-24274 Sentence denotes Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
T698 24275-24659 Sentence denotes Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
T699 24660-24672 Sentence denotes II Primary:
T700 24673-24811 Sentence denotes Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
T701 24812-24833 Sentence denotes Secondary (0–28 day):
T702 24834-25325 Sentence denotes 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
T703 25326-25571 Sentence denotes Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
T704 25572-25603 Sentence denotes Experimental: middle‐dose group
T705 25604-25669 Sentence denotes Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
T706 25670-25699 Sentence denotes Experimental: high‐dose group
T707 25700-25842 Sentence denotes Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
T708 25843-25894 Sentence denotes Secondary (Day 14, 28, Month 3, 6 postvaccination):
T709 25895-26616 Sentence denotes Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
T710 26617-26661 Sentence denotes Other (day、14,28, Month3,6 postvaccination):
T711 26662-27077 Sentence denotes Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
T712 27078-27390 Sentence denotes Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
T713 27391-27507 Sentence denotes We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
T714 27508-27678 Sentence denotes Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
T715 27679-27915 Sentence denotes Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
T716 27916-27972 Sentence denotes Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
T717 27973-28000 Sentence denotes Placebo comparator: placebo
T718 28001-28085 Sentence denotes identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
T719 28086-28114 Sentence denotes All‐cause hospital mortality
T720 28115-28141 Sentence denotes Secondary (up to120 days):
T721 28142-28302 Sentence denotes Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
T722 28303-28489 Sentence denotes Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental:
T723 28490-28511 Sentence denotes Tocilizumab Injection
T724 28512-28625 Sentence denotes Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
T725 28626-28650 Sentence denotes One‐month mortality rate
T726 28651-28677 Sentence denotes Secondary (up to 1 month):
T727 28678-29300 Sentence denotes interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization.
T728 29301-29434 Sentence denotes Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
T729 29435-29528 Sentence denotes Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological:
T730 29529-29612 Sentence denotes NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental:
T731 29613-29623 Sentence denotes NestCell®:
T732 29624-29778 Sentence denotes All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
T733 29779-29829 Sentence denotes Disappear time of ground‐glass shadow in the lungs
T734 29830-29840 Sentence denotes Secondary:
T735 29841-30278 Sentence denotes Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
T736 30279-30497 Sentence denotes CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
T737 30498-30595 Sentence denotes Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
T738 30596-30623 Sentence denotes Placebo comparator: placebo
T739 30624-30723 Sentence denotes Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
T740 30724-30783 Sentence denotes Improvement of COVID‐19 disease status secondary (14 days):
T741 30784-31133 Sentence denotes Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
T742 31134-31314 Sentence denotes Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
T743 31315-31357 Sentence denotes COVID‐19 patients with acute kidney injury
T744 31358-31381 Sentence denotes nonacute kidney injury:
T745 31382-31430 Sentence denotes COVID‐19 patients without acute kidney injury –
T746 31431-31499 Sentence denotes Rate of death, the length of hospital stay Primary (up to 60 days):
T747 31500-31527 Sentence denotes Rate of acute kidney injury
T748 31528-31595 Sentence denotes Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
T749 31596-31776 Sentence denotes Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
T750 31777-31805 Sentence denotes Experimental: low‐dose group
T751 31806-31871 Sentence denotes Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
T752 31872-31903 Sentence denotes Experimental: middle‐dose group
T753 31904-31969 Sentence denotes Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
T754 31970-32106 Sentence denotes Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
T755 32107-32142 Sentence denotes Safety indexes of adverse reactions
T756 32143-32214 Sentence denotes Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
T757 32215-33105 Sentence denotes Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
T758 33106-33149 Sentence denotes Other (Day 14,28, Month 6 postvaccination):
T759 33150-33805 Sentence denotes Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
T760 33806-34076 Sentence denotes Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
T761 34077-34089 Sentence denotes Favipiravir:
T762 34090-34198 Sentence denotes On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day.
T763 34199-34277 Sentence denotes Oral administration, the maximum number of days taken is not more than 7 days.
T764 34278-34354 Sentence denotes Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg.
T765 34355-34542 Sentence denotes For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr.
T766 34543-34564 Sentence denotes Intravenous infusion.
T767 34565-34656 Sentence denotes The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
T768 34657-34693 Sentence denotes Active comparator: favipiravir group
T769 34694-34802 Sentence denotes On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day.
T770 34803-34880 Sentence denotes Oral administration, the maximum number of days taken is not more than 7 days
T771 34881-34917 Sentence denotes Active comparator: tocilizumab group
T772 34918-34981 Sentence denotes The first dose is 4–8 mg/kg and the recommended dose is 400 mg.
T773 34982-35169 Sentence denotes For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr.
T774 35170-35320 Sentence denotes Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
T775 35321-35339 Sentence denotes Clinical cure rate
T776 35340-35382 Sentence denotes Secondary (14 days after taking medicine):
T777 35383-35752 Sentence denotes Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
T778 35753-35973 Sentence denotes Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1.
T779 35974-36070 Sentence denotes 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
T780 36071-36120 Sentence denotes Disppear time of ground‐glass shadow in the lungs
T781 36121-36131 Sentence denotes Secondary:
T782 36132-36310 Sentence denotes Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
T783 36311-36663 Sentence denotes Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
T784 36664-36840 Sentence denotes Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
T785 36841-36895 Sentence denotes Active comparator: control group of ordinary COVID‐19:
T786 36896-36994 Sentence denotes Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
T787 36995-37047 Sentence denotes Experimental: experimental group of severe COVID‐19:
T788 37048-37249 Sentence denotes Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
T789 37250-37342 Sentence denotes Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
T790 37343-37514 Sentence denotes Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
T791 37515-37534 Sentence denotes all‐cause mortality
T792 37535-37555 Sentence denotes Secondary (15 days):
T793 37556-37576 Sentence denotes all‐cause mortality,
T794 37577-37628 Sentence denotes Severe state NCT04292964/Completed Mar1‐Mar13 2020
T795 37629-37867 Sentence denotes Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
T796 37868-37987 Sentence denotes a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
T797 37988-38066 Sentence denotes Placebo comparator: placebo Not applicable Primary (approximately 100 days):
T798 38067-38108 Sentence denotes Number of symptomatic COVID‐19 infections
T799 38109-38144 Sentence denotes Secondary (approximately 100 days):
T800 38145-38413 Sentence denotes Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
T801 38414-38445 Sentence denotes Other (approximately 100 days):
T802 38446-38534 Sentence denotes Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
T803 38535-38607 Sentence denotes Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug:
T804 38608-38638 Sentence denotes YinHu QingWen decoction, drug:
T805 38639-38680 Sentence denotes YinHu QingWen decoction(low dose), other:
T806 38681-38840 Sentence denotes Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental:
T807 38841-38872 Sentence denotes Yin Hu Qing Wen decoction group
T808 38873-38996 Sentence denotes Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
T809 38997-39002 Sentence denotes Drug:
T810 39003-39184 Sentence denotes YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth.
T811 39185-39293 Sentence denotes The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T812 39294-39360 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days
T813 39361-39547 Sentence denotes Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
T814 39548-39567 Sentence denotes Placebo comparator:
T815 39568-39606 Sentence denotes Yinhu Qingwen decoction low‐dose group
T816 39607-39741 Sentence denotes Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
T817 39742-39747 Sentence denotes Drug:
T818 39748-39859 Sentence denotes YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula).
T819 39860-39958 Sentence denotes The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T820 39959-40025 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days
T821 40026-40238 Sentence denotes Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
T822 40239-40303 Sentence denotes Active comparator: integrated Chinese and western medicine group
T823 40304-40443 Sentence denotes Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms.
T824 40444-40588 Sentence denotes The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml).
T825 40589-40680 Sentence denotes The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
T826 40681-40687 Sentence denotes Other:
T827 40688-40714 Sentence denotes Chinese medicine treatment
T828 40715-40852 Sentence denotes This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
T829 40853-40895 Sentence denotes Other: standard western medicine treatment
T830 40896-41069 Sentence denotes Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
T831 41070-41099 Sentence denotes III Primary (up to 28 days):
T832 41100-41127 Sentence denotes Mean clinical recovery time
T833 41128-41154 Sentence denotes Secondary (up to 28 days):
T834 41155-41662 Sentence denotes Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
T835 41663-41962 Sentence denotes Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
T836 41963-42096 Sentence denotes Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
T837 42097-42194 Sentence denotes hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
T838 42195-42202 Sentence denotes Control
T839 42203-42332 Sentence denotes hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
T840 42333-42405 Sentence denotes Occupancy rate in the intensive care unit, mechanical ventilation, death
T841 42406-42432 Sentence denotes Secondary (up to 28 days):
T842 42433-42584 Sentence denotes All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
T843 42585-43046 Sentence denotes Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
T844 43047-43112 Sentence denotes Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
T845 43113-43237 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection.
T846 43238-43307 Sentence denotes Arbidol hydrochloride granules is recommended but not enforced to use
T847 43308-43347 Sentence denotes Recombinant human interferon α2b spray:
T848 43348-43471 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
T849 43472-43491 Sentence denotes Favipiravir tablets
T850 43492-43533 Sentence denotes Active comparator; group B control group:
T851 43534-43570 Sentence denotes Drug: arbidol hydrochloride granules
T852 43571-43765 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
T853 43766-43810 Sentence denotes Drug: recombinant human interferon α2b spray
T854 43811-44006 Sentence denotes Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
T855 44007-44048 Sentence denotes Time to clinical recovery after treatment
T856 44049-44105 Sentence denotes Secondary (within 14 days from the start of medication):
T857 44106-44655 Sentence denotes Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
T858 44656-44934 Sentence denotes Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
T859 44935-45010 Sentence denotes Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
T860 45011-45065 Sentence denotes Experimental: lopinavir and ritonavir plus favipiravir
T861 45066-45242 Sentence denotes Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
T862 45243-45313 Sentence denotes Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
T863 45314-45401 Sentence denotes Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
T864 45402-45478 Sentence denotes Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
T865 45479-45588 Sentence denotes Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
T866 45589-45643 Sentence denotes Experimental: favipiravir lopinavir/ritonavir for mod.
T867 45644-45653 Sentence denotes To severe
T868 45654-45854 Sentence denotes favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
T869 45855-45923 Sentence denotes Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
T870 45924-46093 Sentence denotes Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
T871 46094-46162 Sentence denotes Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
T872 46163-46408 Sentence denotes Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
T873 46409-46448 Sentence denotes No intervention: conventional qurantine
T874 46449-46557 Sentence denotes Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
T875 46558-46585 Sentence denotes SARS‐CoV‐2 eradication time
T876 46586-46613 Sentence denotes Secondary (up to 24 weeks):
T877 46614-46878 Sentence denotes Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
T878 46879-46902 Sentence denotes Other (up to 24 weeks):
T879 46903-47020 Sentence denotes Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
T880 47021-47086 Sentence denotes Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug:
T881 47087-47115 Sentence denotes Yinhu Qingwen granula, drug:
T882 47116-47292 Sentence denotes Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
T883 47293-47321 Sentence denotes Yinhu Qingwen granula group:
T884 47322-47327 Sentence denotes Drug:
T885 47328-47349 Sentence denotes Yinhu Qingwen Granula
T886 47350-47557 Sentence denotes Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc.
T887 47558-47656 Sentence denotes The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T888 47657-47724 Sentence denotes It will be given a 200 ml per time, three times a day, for 10 days.
T889 47725-47929 Sentence denotes Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
T890 47930-47949 Sentence denotes Placebo comparator:
T891 47950-47987 Sentence denotes Yinhu Qingwen granula low‐dose group:
T892 47988-47993 Sentence denotes Drug:
T893 47994-48029 Sentence denotes Yin Hu Qing Wen granula (low does).
T894 48030-48192 Sentence denotes This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
T895 48193-48397 Sentence denotes Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
T896 48399-48420 Sentence denotes II Primary (Day 10):
T897 48421-48471 Sentence denotes changes in the ratio of PaO2 to FiO2 from baseline
T898 48472-48498 Sentence denotes Secondary (up to 30 days):
T899 48499-49275 Sentence denotes PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
T900 49276-49444 Sentence denotes Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
T901 49445-49594 Sentence denotes Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
T902 49595-49816 Sentence denotes Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
T903 49817-49923 Sentence denotes The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
T904 49924-49944 Sentence denotes Secondary (2 weeks):
T905 49945-50404 Sentence denotes Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
T906 50405-50609 Sentence denotes The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental:
T907 50610-50989 Sentence denotes The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
T908 50990-51030 Sentence denotes No intervention: the blank control group
T909 51031-51225 Sentence denotes All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
T910 51227-51401 Sentence denotes Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
T911 51402-51427 Sentence denotes Secondary (Day −1 to 10):
T912 51428-52612 Sentence denotes The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
T913 52613-52709 Sentence denotes Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug:
T914 52710-52851 Sentence denotes Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
T915 52852-52892 Sentence denotes Anti‐PD‐1 antibody, 200 mg, IV, one time
T916 52893-52921 Sentence denotes Experimental: thymosin group
T917 52922-52961 Sentence denotes Thymosin, 1.6 mg sc qd, last for 5 days
T918 52962-53034 Sentence denotes Placebo comparator: control group stand treatment II Primary (7 days):
T919 53035-53052 Sentence denotes lung injury score
T920 53053-53063 Sentence denotes Secondary:
T921 53064-53334 Sentence denotes Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
T922 53335-53604 Sentence denotes Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
T923 53605-53742 Sentence denotes Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min.
T924 53743-53818 Sentence denotes Tocilizumab was administered according—continuous renal replacement therapy
T925 53819-53966 Sentence denotes Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
T926 53967-53980 Sentence denotes Standard care
T927 53981-54075 Sentence denotes Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
T928 54076-54152 Sentence denotes Proportion of participants with normalization of fever and oxygen saturation
T929 54153-54163 Sentence denotes Secondary:
T930 54164-54743 Sentence denotes Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
T931 54744-55007 Sentence denotes Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
T932 55008-55081 Sentence denotes caregivers from emergency, ICU, virology and infectious disease services:
T933 55082-55155 Sentence denotes Two blood samples at T0 and 3 months Not applicable Primary (3 months):
T934 55156-55263 Sentence denotes Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
T935 55264-55285 Sentence denotes Secondary (3 months):
T936 55286-55579 Sentence denotes Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
T937 55580-55603 Sentence denotes John Wiley & Sons, Ltd.
T938 55604-55728 Sentence denotes This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T939 55729-55911 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T216 2450-2459 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T217 2881-2886 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T218 3048-3053 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T219 4275-4280 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T220 4845-4864 Phenotype denotes respiratory failure http://purl.obolibrary.org/obo/HP_0002878
T221 8340-8345 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T222 9577-9586 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T223 9626-9635 Phenotype denotes Pneumonia http://purl.obolibrary.org/obo/HP_0002090
T224 10066-10075 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T225 10577-10582 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T226 13637-13646 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T227 13725-13734 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T228 16075-16098 Phenotype denotes cardiovascular diseases http://purl.obolibrary.org/obo/HP_0001626
T229 18326-18331 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T230 19619-19624 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T231 20059-20064 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T232 20149-20154 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T233 20397-20402 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T234 20650-20655 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T235 20774-20783 Phenotype denotes hypoxemia http://purl.obolibrary.org/obo/HP_0012418
T236 21385-21408 Phenotype denotes opportunistic infection http://purl.obolibrary.org/obo/HP_0031690
T237 21481-21504 Phenotype denotes opportunistic infection http://purl.obolibrary.org/obo/HP_0031690
T238 21530-21541 Phenotype denotes neutropenia http://purl.obolibrary.org/obo/HP_0001875
T239 21556-21572 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T240 23660-23669 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T241 23687-23696 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T242 23817-23826 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T243 23852-23861 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T244 27728-27747 Phenotype denotes pulmonary infection http://purl.obolibrary.org/obo/HP_0006532
T245 28327-28336 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T246 28395-28404 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T247 29506-29515 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T248 29549-29558 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T249 29930-29935 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T250 31134-31153 Phenotype denotes Acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T251 31212-31231 Phenotype denotes acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T252 31294-31313 Phenotype denotes Acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T253 31338-31357 Phenotype denotes acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T254 31408-31427 Phenotype denotes acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T255 31508-31527 Phenotype denotes acute kidney injury http://purl.obolibrary.org/obo/HP_0001919
T256 34359-34364 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T257 34454-34459 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T258 34986-34991 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T259 35081-35086 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T260 35480-35485 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T261 35642-35661 Phenotype denotes respiratory failure http://purl.obolibrary.org/obo/HP_0002878
T262 35786-35795 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T263 36434-36443 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T264 37773-37794 Phenotype denotes respiratory illnesses http://purl.obolibrary.org/obo/HP_0002086
T265 38268-38289 Phenotype denotes respiratory illnesses http://purl.obolibrary.org/obo/HP_0002086
T266 41384-41389 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T267 41414-41419 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T268 41462-41467 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T269 41517-41524 Phenotype denotes dyspnea http://purl.obolibrary.org/obo/HP_0002094
T270 41612-41619 Phenotype denotes dyspnea http://purl.obolibrary.org/obo/HP_0002094
T271 42020-42032 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T272 42097-42109 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T273 42203-42215 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T274 42762-42771 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T275 42960-42969 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T276 43164-43173 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T277 43399-43408 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T278 43622-43631 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T279 43862-43871 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T280 44249-44254 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T281 46833-46853 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T282 46932-46952 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T283 47210-47219 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T284 49537-49546 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T285 49636-49645 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T286 49679-49688 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T287 49957-49962 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T288 50109-50129 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T289 50211-50216 Phenotype denotes shock http://purl.obolibrary.org/obo/HP_0031273
T290 50218-50231 Phenotype denotes renal failure http://purl.obolibrary.org/obo/HP_0000083
T291 50257-50273 Phenotype denotes hemophagocytosis http://purl.obolibrary.org/obo/HP_0012156
T292 50557-50566 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T293 51488-51495 Phenotype denotes fatigue http://purl.obolibrary.org/obo/HP_0012378
T294 51497-51513 Phenotype denotes nausea, vomiting http://purl.obolibrary.org/obo/HP_0002017
T295 51515-51530 Phenotype denotes chest tightness http://purl.obolibrary.org/obo/HP_0031352
T296 51532-51551 Phenotype denotes shortness of breath http://purl.obolibrary.org/obo/HP_0002098
T297 52366-52374 Phenotype denotes acidosis http://purl.obolibrary.org/obo/HP_0001941
T298 53372-53397 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T299 53531-53545 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T300 54125-54130 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T301 54258-54263 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1806 806-810 Gene denotes Sep1 Gene:1731
1807 1779-1810 Gene denotes angiotensin‐converting enzyme 2 Gene:59272
1808 1887-1918 Gene denotes angiotensin‐converting enzyme 2 Gene:59272
1809 2492-2510 Gene denotes C‐reactive protein Gene:1401
1810 2529-2543 Gene denotes angiotensin II Gene:183
1811 2545-2551 Gene denotes Ang II Gene:183
1812 2589-2596 Gene denotes Ang 1–7 Gene:284
1813 2634-2641 Gene denotes Ang 1–5 Gene:284
1814 2718-2747 Gene denotes angiotensin‐converting enzyme Gene:1636
1815 2767-2798 Gene denotes angiotensin‐converting enzyme 2 Gene:59272
1816 2800-2804 Gene denotes ACE2 Gene:59272
1817 2825-2829 Gene denotes IL‐6 Gene:3569
1818 2849-2853 Gene denotes IL‐8 Gene:3576
1819 2881-2919 Gene denotes tumor necrosis factor receptor type II Gene:7133
1820 3048-3071 Gene denotes tumor necrosis factor‐α Gene:7124
1821 3211-3225 Gene denotes angiopoietin‐2 Gene:285
1822 4360-4378 Gene denotes C‐reactive protein Gene:1401
1823 4380-4383 Gene denotes CRP Gene:1401
1824 11008-11013 Gene denotes TNF‐α Gene:7124
1825 11015-11020 Gene denotes IL‐1β Gene:3552
1826 11022-11026 Gene denotes IL‐2 Gene:3558
1827 11028-11032 Gene denotes IL‐6 Gene:3569
1828 11034-11038 Gene denotes IL‐7 Gene:3574
1829 11040-11045 Gene denotes IL‐10 Gene:3586
1830 11053-11057 Gene denotes IP10 Gene:3627
1831 11059-11063 Gene denotes MCP1 Gene:6347
1832 11065-11070 Gene denotes MIP1α Gene:6348
1833 12611-12616 Gene denotes TNF‐α Gene:7124
1834 12618-12623 Gene denotes IL‐1β Gene:3552
1835 12625-12629 Gene denotes IL‐2 Gene:3558
1836 12631-12635 Gene denotes IL‐6 Gene:3569
1837 12637-12641 Gene denotes IL‐7 Gene:3574
1838 12643-12648 Gene denotes IL‐10 Gene:3586
1839 12656-12660 Gene denotes IP10 Gene:3627
1840 12661-12665 Gene denotes MCP1 Gene:6347
1841 12667-12672 Gene denotes MIP1α Gene:6348
1842 14609-14612 Gene denotes CD4 Gene:920
1843 14619-14622 Gene denotes CD8 Gene:925
1844 14677-14682 Gene denotes IL‐1β Gene:3552
1845 14684-14688 Gene denotes IL‐6 Gene:3569
1846 14690-14694 Gene denotes IL‐8 Gene:3576
1847 14695-14700 Gene denotes IL‐10 Gene:3586
1848 14701-14706 Gene denotes TNF‐α Gene:7124
1849 15365-15368 Gene denotes Apr Gene:5366
1850 15823-15836 Gene denotes serum albumin Gene:213
1851 16752-16765 Gene denotes serum albumin Gene:213
1852 17205-17218 Gene denotes serum albumin Gene:213
1853 17737-17740 Gene denotes CD4 Gene:920
1854 20207-20211 Gene denotes IL‐6 Gene:3569
1855 20362-20366 Gene denotes IL‐6 Gene:3569
1856 21761-21785 Gene denotes alanine aminotransferase Gene:2875
1857 28678-28691 Gene denotes interleukin‐6 Gene:3569
1858 28717-28735 Gene denotes C‐reactive protein Gene:1401
1859 30042-30045 Gene denotes CD4 Gene:920
1860 30051-30054 Gene denotes CD8 Gene:925
1861 30266-30269 Gene denotes Apr Gene:5366
1862 33340-33349 Gene denotes S protein Gene:43740568
1863 36795-36834 Gene denotes alpha‐interferon nebulization, for 7–14
1864 37179-37218 Gene denotes alpha‐interferon nebulization, for 7–14
1865 42886-42900 Gene denotes interferon α2b Gene:3440
1866 43326-43340 Gene denotes interferon α2b Gene:3440
1867 43790-43804 Gene denotes interferon α2b Gene:3440
1868 52602-52607 Gene denotes Sep15 Gene:9403
1869 52659-52663 Gene denotes PD‐1 Gene:6622
1870 53127-53130 Gene denotes CRP Gene:1401
1871 53140-53144 Gene denotes IL‐6 Gene:3569
1872 54560-54565 Gene denotes IL‐1β Gene:3552
1873 54567-54572 Gene denotes IL‐10 Gene:3586
1874 54582-54586 Gene denotes IL‐6 Gene:3569
1875 54588-54592 Gene denotes IL‐8 Gene:3576
1876 54597-54602 Gene denotes TNF‐α Gene:7124
1877 54658-54661 Gene denotes CD4 Gene:920
1878 54668-54671 Gene denotes CD8 Gene:925
1879 1648-1651 Gene denotes CRP Gene:1401
1880 1773-1778 Species denotes human Tax:9606
1881 1839-1847 Species denotes patients Tax:9606
1882 1881-1886 Species denotes human Tax:9606
1883 4605-4613 Species denotes patients Tax:9606
1884 4756-4764 Species denotes patients Tax:9606
1885 6217-6229 Species denotes participants Tax:9606
1886 6309-6321 Species denotes participants Tax:9606
1887 6512-6520 Species denotes patients Tax:9606
1888 7736-7748 Species denotes participants Tax:9606
1889 7944-7956 Species denotes participants Tax:9606
1890 8119-8131 Species denotes participants Tax:9606
1891 8305-8317 Species denotes participants Tax:9606
1892 8408-8420 Species denotes participants Tax:9606
1893 8649-8661 Species denotes participants Tax:9606
1894 8884-8896 Species denotes participants Tax:9606
1895 9060-9072 Species denotes participants Tax:9606
1896 9317-9329 Species denotes participants Tax:9606
1897 9392-9404 Species denotes participants Tax:9606
1898 9554-9562 Species denotes patients Tax:9606
1899 9826-9834 Species denotes patients Tax:9606
1900 10039-10054 Species denotes new coronavirus Tax:2697049
1901 10726-10735 Species denotes 2019‐nCoV Tax:2697049
1902 10811-10820 Species denotes 2019‐nCoV Tax:2697049
1903 12411-12420 Species denotes 2019‐nCoV Tax:2697049
1904 12451-12460 Species denotes 2019‐nCoV Tax:2697049
1905 13435-13442 Species denotes patient Tax:9606
1906 13735-13743 Species denotes patients Tax:9606
1907 13756-13778 Species denotes 2019 novel coronavirus Tax:2697049
1908 13899-13911 Species denotes participants Tax:9606
1909 14075-14087 Species denotes participants Tax:9606
1910 14872-14882 Species denotes SARS‐CoV‐2 Tax:2697049
1911 15400-15408 Species denotes patients Tax:9606
1912 15667-15671 Species denotes HIV1 Tax:11676
1913 15859-15866 Species denotes patient Tax:9606
1914 16212-16219 Species denotes patient Tax:9606
1915 16309-16316 Species denotes patient Tax:9606
1916 16657-16669 Species denotes corona virus Tax:11118
1917 16905-16917 Species denotes participants Tax:9606
1918 17104-17116 Species denotes participants Tax:9606
1919 17443-17451 Species denotes patients Tax:9606
1920 17917-17925 Species denotes patients Tax:9606
1921 19127-19135 Species denotes patients Tax:9606
1922 19705-19713 Species denotes patients Tax:9606
1923 20667-20675 Species denotes patients Tax:9606
1924 20928-20936 Species denotes patients Tax:9606
1925 20995-21003 Species denotes patients Tax:9606
1926 21049-21057 Species denotes patients Tax:9606
1927 21114-21122 Species denotes patients Tax:9606
1928 21508-21516 Species denotes patients Tax:9606
1929 21911-21919 Species denotes patients Tax:9606
1930 21925-21934 Species denotes 2019‐nCoV Tax:2697049
1931 22565-22577 Species denotes participants Tax:9606
1932 23207-23215 Species denotes patients Tax:9606
1933 23310-23318 Species denotes patients Tax:9606
1934 23630-23638 Species denotes patients Tax:9606
1935 24523-24531 Species denotes patients Tax:9606
1936 24931-24939 Species denotes patients Tax:9606
1937 25020-25028 Species denotes patients Tax:9606
1938 25123-25131 Species denotes patients Tax:9606
1939 25391-25408 Species denotes novel coronavirus Tax:2697049
1940 25418-25435 Species denotes adenovirus type 5 Tax:28285
1941 25548-25552 Species denotes nCoV Tax:2697049
1942 25646-25650 Species denotes nCoV Tax:2697049
1943 25743-25747 Species denotes nCoV Tax:2697049
1944 27112-27127 Species denotes new coronavirus Tax:2697049
1945 27486-27494 Species denotes patients Tax:9606
1946 28411-28416 Species denotes child Tax:9606
1947 28438-28443 Species denotes child Tax:9606
1948 29048-29060 Species denotes participants Tax:9606
1949 29333-29340 Species denotes patient Tax:9606
1950 29476-29484 Species denotes patients Tax:9606
1951 29628-29636 Species denotes patients Tax:9606
1952 30394-30405 Species denotes coronavirus Tax:11118
1953 31157-31165 Species denotes patients Tax:9606
1954 31324-31332 Species denotes patients Tax:9606
1955 31391-31399 Species denotes patients Tax:9606
1956 31658-31675 Species denotes novel coronavirus Tax:2697049
1957 31685-31702 Species denotes adenovirus type 5 Tax:28285
1958 31751-31768 Species denotes Adenovirus Type 5 Tax:28285
1959 31848-31852 Species denotes nCoV Tax:2697049
1960 31946-31950 Species denotes nCoV Tax:2697049
1961 32043-32047 Species denotes nCoV Tax:2697049
1962 33864-33876 Species denotes corona virus Tax:11118
1963 34365-34373 Species denotes patients Tax:9606
1964 34992-35000 Species denotes patients Tax:9606
1965 35544-35556 Species denotes corona virus Tax:11118
1966 35753-35770 Species denotes Novel coronavirus Tax:2697049
1967 36408-36423 Species denotes new coronavirus Tax:2697049
1968 37365-37373 Species denotes patients Tax:9606
1969 37398-37408 Species denotes SARS‐CoV‐2 Tax:2697049
1970 37467-37477 Species denotes SARS‐CoV‐2 Tax:2697049
1971 37655-37666 Species denotes coronavirus Tax:11118
1972 37747-37766 Species denotes COVID19 coronavirus Tax:2697049
1973 38927-38935 Species denotes patients Tax:9606
1974 39083-39098 Species denotes herbal medicine Tax:1407750
1975 39115-39135 Species denotes Polygonum cuspidatum Tax:83819
1976 39661-39669 Species denotes patients Tax:9606
1977 40358-40366 Species denotes patients Tax:9606
1978 40832-40840 Species denotes patients Tax:9606
1979 41994-42002 Species denotes patients Tax:9606
1980 42110-42118 Species denotes patients Tax:9606
1981 42158-42175 Species denotes novel coronavirus Tax:2697049
1982 42216-42224 Species denotes patients Tax:9606
1983 42267-42284 Species denotes novel coronavirus Tax:2697049
1984 42711-42719 Species denotes patients Tax:9606
1985 42744-42761 Species denotes novel coronavirus Tax:2697049
1986 42880-42885 Species denotes human Tax:9606
1987 42942-42959 Species denotes novel coronavirus Tax:2697049
1988 42970-42979 Species denotes 2019‐nCoV Tax:2697049
1989 43209-43226 Species denotes novel coronavirus Tax:2697049
1990 43320-43325 Species denotes human Tax:9606
1991 43444-43461 Species denotes novel coronavirus Tax:2697049
1992 43667-43684 Species denotes novel coronavirus Tax:2697049
1993 43784-43789 Species denotes human Tax:9606
1994 43907-43924 Species denotes novel coronavirus Tax:2697049
1995 44307-44315 Species denotes patients Tax:9606
1996 44359-44367 Species denotes patients Tax:9606
1997 44817-44828 Species denotes coronavirus Tax:11118
1998 46558-46568 Species denotes SARS‐CoV‐2 Tax:2697049
1999 46624-46631 Species denotes patient Tax:9606
2000 46654-46661 Species denotes patient Tax:9606
2001 46809-46816 Species denotes patient Tax:9606
2002 46913-46920 Species denotes patient Tax:9606
2003 47465-47480 Species denotes herbal medicine Tax:1407750
2004 47497-47517 Species denotes Polygonum cuspidatum Tax:83819
2005 48904-48912 Species denotes patients Tax:9606
2006 48923-48932 Species denotes 2019‐nCoV Tax:2697049
2007 49328-49337 Species denotes 2019‐nCoV Tax:2697049
2008 49351-49359 Species denotes children Tax:9606
2009 49371-49380 Species denotes 2019‐nCoV Tax:2697049
2010 49419-49428 Species denotes 2019‐nCoV Tax:2697049
2011 49503-49520 Species denotes novel coronavirus Tax:2697049
2012 49569-49578 Species denotes 2019‐nCoV Tax:2697049
2013 49609-49617 Species denotes Children Tax:9606
2014 49661-49678 Species denotes novel coronavirus Tax:2697049
2015 49731-49740 Species denotes 2019‐nCoV Tax:2697049
2016 49834-49843 Species denotes 2019‐nCoV Tax:2697049
2017 49869-49878 Species denotes 2019‐nCoV Tax:2697049
2018 50037-50048 Species denotes participant Tax:9606
2019 50083-50094 Species denotes participant Tax:9606
2020 50150-50161 Species denotes participant Tax:9606
2021 50302-50313 Species denotes participant Tax:9606
2022 50479-50487 Species denotes patients Tax:9606
2023 50514-50525 Species denotes Coronavirus Tax:11118
2024 50534-50556 Species denotes 2019 novel coronavirus Tax:2697049
2025 51348-51356 Species denotes patients Tax:9606
2026 51467-51475 Species denotes patients Tax:9606
2027 51668-51676 Species denotes patients Tax:9606
2028 51831-51839 Species denotes patients Tax:9606
2029 51974-51982 Species denotes patients Tax:9606
2030 52117-52125 Species denotes patients Tax:9606
2031 52203-52211 Species denotes patients Tax:9606
2032 52352-52360 Species denotes patients Tax:9606
2033 52402-52410 Species denotes patients Tax:9606
2034 52642-52651 Species denotes 2019‐nCoV Tax:2697049
2035 52769-52778 Species denotes 2019 nCoV Tax:2697049
2036 54090-54102 Species denotes participants Tax:9606
2037 54223-54235 Species denotes participants Tax:9606
2038 54388-54411 Species denotes 2019 novel corona virus Tax:2697049
2039 54744-54753 Species denotes Sars‐CoV2 Tax:2697049
2040 54941-54950 Species denotes Sars‐CoV2 Tax:2697049
2041 54964-54969 Species denotes child Tax:9606
2042 55183-55191 Species denotes patients Tax:9606
2043 55208-55217 Species denotes Sars‐CoV2 Tax:2697049
2044 54855-54865 Species denotes infectious Tax:11120
2045 55053-55063 Species denotes infectious Tax:11120
2046 15817-15822 Species denotes human Tax:9606
2047 16746-16751 Species denotes human Tax:9606
2048 17199-17204 Species denotes human Tax:9606
2049 3326-3329 Gene denotes Apr Gene:5366
2050 52857-52861 Gene denotes PD‐1 Gene:6622
2051 52841-52845 Gene denotes PD‐1 Gene:6622
2052 52780-52784 Gene denotes PD‐1 Gene:6622
2053 26810-26819 Gene denotes S protein Gene:43740568
2054 5735-5753 Chemical denotes hydroxychloroquine MESH:D006886
2055 6467-6486 Chemical denotes lopinavir/ritonavir MESH:C558899
2056 6569-6588 Chemical denotes lopinavir/ritonavir MESH:C558899
2057 6697-6716 Chemical denotes lopinavir/ritonavir MESH:C558899
2058 6897-6916 Chemical denotes lopinavir/ritonavir MESH:C558899
2059 7416-7435 Chemical denotes lopinavir/ritonavir MESH:C558899
2060 7518-7537 Chemical denotes lopinavir/ritonavir MESH:C558899
2061 7711-7721 Chemical denotes remdesivir MESH:C000606551
2062 7799-7809 Chemical denotes remdesivir MESH:C000606551
2063 8099-8109 Chemical denotes remdesivir MESH:C000606551
2064 8624-8634 Chemical denotes remdesivir MESH:C000606551
2065 8753-8763 Chemical denotes remdesivir MESH:C000606551
2066 8865-8875 Chemical denotes remdesivir MESH:C000606551
2067 9040-9050 Chemical denotes remdesivir MESH:C000606551
2068 11506-11511 Chemical denotes water MESH:D014867
2069 11696-11707 Chemical denotes thalidomide MESH:D013792
2070 11803-11808 Chemical denotes water MESH:D014867
2071 11851-11857 Chemical denotes abidol
2072 11899-11917 Chemical denotes methylprednisolone MESH:D008775
2073 17965-17984 Chemical denotes lopinavir/ritonavir MESH:C558899
2074 18157-18176 Chemical denotes lopinavir/ritonavir MESH:C558899
2075 18238-18257 Chemical denotes lopinavir/ritonavir MESH:C558899
2076 21719-21729 Chemical denotes creatinine MESH:D003404
2077 34278-34289 Chemical denotes Tocilizumab MESH:C502936
2078 34676-34687 Chemical denotes favipiravir MESH:C462182
2079 34900-34911 Chemical denotes tocilizumab MESH:C502936
2080 36472-36491 Chemical denotes lopinavir/ritonavir MESH:C558899
2081 36540-36559 Chemical denotes lopinavir/ritonavir MESH:C558899
2082 36756-36765 Chemical denotes lopinavir MESH:D061466
2083 36896-36915 Chemical denotes Lopinavir/ritonavir MESH:C558899
2084 37140-37149 Chemical denotes lopinavir MESH:D061466
2085 43238-43259 Chemical denotes Arbidol hydrochloride
2086 43540-43561 Chemical denotes arbidol hydrochloride
2087 45025-45034 Chemical denotes lopinavir MESH:D061466
2088 45257-45266 Chemical denotes lopinavir MESH:D061466
2089 45416-45425 Chemical denotes lopinavir MESH:D061466
2090 45615-45634 Chemical denotes lopinavir/ritonavir MESH:C558899
2091 52244-52251 Chemical denotes heparin MESH:D006493
2092 53743-53754 Chemical denotes Tocilizumab MESH:C502936
2093 258-266 Disease denotes COVID‐19 MESH:C000657245
2094 290-298 Disease denotes COVID‐19 MESH:C000657245
2095 894-902 Disease denotes COVID‐19 MESH:C000657245
2096 935-943 Disease denotes COVID‐19 MESH:C000657245
2097 1853-1861 Disease denotes COVID‐19 MESH:C000657245
2098 1935-1943 Disease denotes COVID‐19 MESH:C000657245
2099 2223-2236 Disease denotes organ failure MESH:D009102
2100 2370-2386 Disease denotes critical illness MESH:D016638
2101 2390-2395 Disease denotes death MESH:D003643
2102 2450-2459 Disease denotes pneumonia MESH:D011014
2103 3007-3021 Disease denotes Von willebrand MESH:D014842
2104 3339-3347 Disease denotes COVID‐19 MESH:C000657245
2105 3430-3438 Disease denotes COVID‐19 MESH:C000657245
2106 3618-3623 Disease denotes COVID MESH:C000657245
2107 3780-3788 Disease denotes COVID‐19 MESH:C000657245
2108 3828-3836 Disease denotes COVID‐19 MESH:C000657245
2109 3934-3942 Disease denotes COVID‐19 MESH:C000657245
2110 3989-3997 Disease denotes COVID‐19 MESH:C000657245
2111 4275-4280 Disease denotes fever MESH:D005334
2112 4590-4604 Disease denotes Critically Ill MESH:D016638
2113 4619-4627 Disease denotes COVID‐19 MESH:C000657245
2114 4697-4705 Disease denotes COVID‐19 MESH:C000657245
2115 4845-4864 Disease denotes respiratory failure MESH:D012131
2116 4957-4966 Disease denotes mortality MESH:D003643
2117 5331-5339 Disease denotes COVID‐19 MESH:C000657245
2118 5426-5434 Disease denotes COVID‐19 MESH:C000657245
2119 6029-6037 Disease denotes COVID‐19 MESH:C000657245
2120 6164-6173 Disease denotes mortality MESH:D003643
2121 6531-6550 Disease denotes coronavirus disease MESH:D018352
2122 6552-6560 Disease denotes COVID‐19 MESH:C000657245
2123 6630-6638 Disease denotes COVID‐19 MESH:C000657245
2124 7333-7338 Disease denotes death MESH:D003643
2125 7761-7780 Disease denotes coronavirus disease MESH:D018352
2126 7782-7790 Disease denotes COVID‐19 MESH:C000657245
2127 7854-7862 Disease denotes COVID‐19 MESH:C000657245
2128 8340-8345 Disease denotes fever MESH:D005334
2129 8676-8695 Disease denotes coronavirus disease MESH:D018352
2130 8697-8705 Disease denotes COVID‐19 MESH:C000657245
2131 9568-9586 Disease denotes COVID‐19 pneumonia MESH:C000657245
2132 9617-9635 Disease denotes COVID‐19 Pneumonia MESH:C000657245
2133 10056-10064 Disease denotes COVID‐19 MESH:C000657245
2134 10066-10075 Disease denotes pneumonia MESH:D011014
2135 10105-10113 Disease denotes COVID‐19 MESH:C000657245
2138 46-50 Species denotes nCoV Tax:2697049
2139 29-37 Disease denotes COVID‐19 MESH:C000657245
2141 55686-55694 Disease denotes COVID-19 MESH:C000657245